EXHIBIT 107
Calculation of Filing Fee Tables
Form S-3
(Form Type)
FibroBiologics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1 - Newly Registered and Carry Forward Securities
| Security Type | Security Class Title | Fee Calculation or Carry Forward Rule | Amount Registered | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | Carry Forward Form Type | Carry Forward File Number | Carry Forward Initial Effective Date | Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward | |||||||||||||||||||||||||||||||
| Newly Registered Securities | ||||||||||||||||||||||||||||||||||||||||||
| Fees to Be Paid | Equity | Common Stock, par value $0.00001 per share | 457(o) | (2) (3) | (3) | (3) | ||||||||||||||||||||||||||||||||||||
| Equity | Preferred Stock, par value $0.00001 per share | 457(o) | (2) (3) | (3) | (3) | |||||||||||||||||||||||||||||||||||||
| Equity | Depositary Shares | 457(o) | (2) (3) | (3) | (3) | |||||||||||||||||||||||||||||||||||||
| Other | Warrants | 457(o) | (2) (3) | (3) | (3) | |||||||||||||||||||||||||||||||||||||
| Other | Subscription Rights | 457(o) | (2) (3) | (3) | (3) | |||||||||||||||||||||||||||||||||||||
| Other | Contingent Value Rights | 457(o) | (2) (3) | (3) | (3) | |||||||||||||||||||||||||||||||||||||
| Debt | Debt Securities | 457(o) | (2) (3) | (3) | (3) | |||||||||||||||||||||||||||||||||||||
| Other | Purchase Contracts | 457(o) | (2) (3) | (3) | (3) | |||||||||||||||||||||||||||||||||||||
| Other | Units(1) | 457(o) | (2) (3) | (3) | (3) | |||||||||||||||||||||||||||||||||||||
| Unallocated (Universal) Shelf | - | 457(o) | (2) (3) | (3) | $ | 50,000,000 | $153.10 per $1,000,000 | $ | 7,655 | |||||||||||||||||||||||||||||||||
| Fees Previously Paid | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Carry Forward Securities | ||||||||||||||||||||||||||||||||||||||||||
| Carry Forward Securities | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Total Offering Amounts | $ | 50,000,000 | $ | 7,655 | ||||||||||||||||||||||||||||||||||||||
| Total Fees Previously Paid | - | |||||||||||||||||||||||||||||||||||||||||
| Total Fee Offsets | $ | 2,877.72 | ||||||||||||||||||||||||||||||||||||||||
| Net Fee Due | $ | 4,777.28 | ||||||||||||||||||||||||||||||||||||||||
Table 2 – Fee Offset Claims and Sources
| Registrant or Filer Name | Form or Filing Type | File Number | Initial Filing Date | Filing Date | Fee Offset Claimed | Security Type Associated with Fee Offset Claimed | Security Title Associated with Fee Offset Claimed | Unsold Securities Associated with Fee Offset Claimed | Unsold Aggregate Offering Amount Associated with Fee Offset Claimed | Fee Paid with Fee Offset Source | ||||||||||||||||||||||||
| Rule 457(p) | ||||||||||||||||||||||||||||||||||
| Fee Offset Claims | FibroBiologics, Inc. | S-1 | 333-277019(4) | February 12, 2024 | March 15, 2024 | $ | 2,877.72 | Equity | Shares of Common Stock, par value $0.00001 per share, underlying warrants | 1,299,783 | $ | 19,496,745 | - | |||||||||||||||||||||
| Fees Offset Sources | FibroBiologics, Inc. | S-1 | 333-277019(4) | February 12, 2024 | March 15, 2024 | - | - | - | - | - | $ | 2,877.72 | ||||||||||||||||||||||
| (1) | Consisting of some or all of the securities listed above, in any combination. |
| (2) | There is being registered hereunder an indeterminate (a) number of shares of common stock, (b) number of shares of preferred stock, (c) number of depositary shares to be evidenced by depositary receipts issued pursuant to a deposit agreement, (d) number of warrants that may represent the right to purchase shares of common stock, shares of preferred stock, depositary shares, contingent value rights or debt securities, (e) number of subscription rights that may represent a right to purchase shares of common stock, shares of preferred stock, depositary shares, contingent value rights or debt securities, (f) number of contingent value rights that represent a right to potential cash payment upon the satisfaction of one or more conditions set forth in a contingent value rights agreement, (g) principal amount of debt securities, (h) number of purchase contracts and (i) number of units that will be issued under a unit agreement and will represent an interest in a combination of one or more of the securities registered hereunder. If the registrant elects to offer to the public fractional interests in shares of preferred stock, then depositary receipts will be distributed to those persons purchasing the fractional interests and the shares of preferred stock will be issued to the depositary under the deposit agreement. The securities registered also include such indeterminate amount of securities as may be issued in exchange for, or upon conversion or exercise of, as the case may be, the preferred stock, depositary shares, warrants or subscription rights registered hereunder or pursuant to the antidilution provisions of any such securities. Any securities registered hereunder may be sold separately or as units with other securities registered hereunder. No separate consideration will be received for any securities registered hereunder that are issued in exchange for, or upon conversion of, as the case may be, the preferred stock, depositary shares, warrants or subscription rights. In no event will the aggregate offering price of all types of securities issued by the registrant pursuant to this registration statement exceed $50,000,000. If any debt securities are issued at an original issue discount, then the principal amount of such debt securities shall be in such greater amount as shall result in an aggregate initial offering price not to exceed $50,000,000, less the aggregate dollar amount of all securities previously issued hereunder. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also covers such indeterminate number of securities as may be issuable with respect to the securities being registered hereunder as a result of stock splits, stock dividends or similar transactions. |
| (3) | The amount registered, the proposed maximum offering price per unit and the maximum aggregate offering price for each class of security will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and are not specified as to each class of security pursuant to Instructions 2.A.ii.b. and 2.A.iii.b. to the Calculation of Filing Fee Tables and Related Disclosure under Item 16(b) of Form S-3 under the Securities Act. |
| (4) | On January 17, 2025, FibroBiologics, Inc. (the “Company”) filed a Post-Effective Amendment No. 1 to the registration statement on Form S-1 (File No. 333-277019) (the “S-1 Registration Statement”) to terminate the effectiveness of the S-1 Registration Statement and to remove from registration all securities registered but not sold under the S-1 Registration Statement. Pursuant to Rule 457(p) under the Securities Act, the Company is offsetting $2,877.72 of the fee previously paid by the Company in connection with the S-1 Registration Statement associated with unsold securities. |
